

Remarks/Arguments

The Examiner has required that applicants elect a single invention to which the claims must be restricted.


Applicants elect Group I, i.e., claims 1-8 and 10, and the peptide of formula II. Claims 1-8, 10, and new claims 11 and 12, read on the peptide chosen.

Applicants further elect the species of Cushing's Disease. Claim 9 has been cancelled and claims 7 and 8, and new claims 13 and 14, are readable on the species of Cushing's Disease.

New claims 11- 14 have been added. Claims 11 and 12 recite the compositions of Claims 1 and 3 comprising the peptide of Claim 5. Claims 13 and 14 recite the elected species of Cushing's disease, to be treated with the pharmaceutical composition of new claims 11 and 12. No new matter has been added.

Applicants respectfully submit that the present claims are in condition for allowance, which action is earnestly solicited.

Respectfully submitted,



Lydia T. McNally
Attorney for Applicants
Reg. No. 36,214

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7898

Date: March 21, 2007